Biotech Values

[DewDiligence]

FMTX IPOs 15.9M shares @$20.00:

Forma Therapeutics (FMTX) priced 13.8mm shares (upsized from 11.6mm) at $20.00 ($2.00 above range) and will debut on Friday. #IPO $FMTX pic.twitter.com/jADxqBiF3k

— IPO Boutique (@IPOBoutique) June 18, 2020

https://www.sec.gov/Archives/edgar/data/1538927/000119312520155670/d906114ds1.htm#toc906114_13

[Forma Therapeutics] is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers… Our pipeline consists of seven product candidates, two of which we are pursuing as core product candidates for development, FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

*Assuming exercise of underwriter’s option.